Rottapharm Biotech is dedicated to the discovery and development of innovative drugs, with a strong emphasis on rheumatic diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). The company employs a multilevel approach to create both symptom-modifying and disease-modifying drugs, leveraging the expertise of its internationally recognized scientists. Their research and development efforts are focused on developing new immunomodulators that serve as innovative disease-modifying anti-rheumatic drugs (DMARDs) for RA and other autoimmune disorders. Currently, Rottapharm Biotech has four active projects within a coherent rheumatology platform, alongside two additional projects targeting unmet medical needs in oncology and immuno-oncology.

The company’s strategy includes seeking partnerships at early stages of drug development, ranging from significant preclinical phases to Phase II proof-of-concept clinical trials. This collaborative approach allows Rottapharm Biotech to enhance its research capabilities and accelerate the development of its therapeutic offerings. The commitment to innovation and strategic partnerships underscores Rottapharm Biotech's mission to address critical health challenges through the advancement of novel therapeutic solutions.

Italy

Discovering and developing novel drugs has been our passion, work and mission for over 50 years. Rottapharm Biotech lives for innovation and innovation lives at Rottapharm Biotech. This is all we are and all we want to be.



Rottapharm Biotech

Company Details